Druckenmiller dumps Alphabet, Amazon, buys Broadcom in Q1 2026

Stanley Druckenmiller is one of the most-watched money managers on Wall Street, and his Duquesne Family Office Q1 2026 13F filing just landed.

The headline number is brutal for Alphabet bulls. Duquesne sold all 385,000 shares of Alphabet (GOOGL) Class A stock during the quarter. That same stake had been aggressively built up just one quarter earlier, from roughly 102,000 shares to 385,000.

Amazon got the same treatment. Duquesne cut its Amazon (AMZN) position from 737,940 shares down to just 9,539 shares, a 99% reduction.

Where did the money go? Mostly into Broadcom (AVGO), the AI custom silicon maker that has quietly become one of the most important chip suppliers in the AI build-out behind Nvidia.

Druckenmiller opened a fresh 195,955-share Broadcom stake, alongside smaller new bets in cancer-diagnostics player Caris Life Sciences (1.89 million shares) and clinical-stage drug developer Revolution Medicines (315,860 shares), according to CoinCentral's filing breakdown.

This matters because Druckenmiller has publicly admitted that selling Nvidia between $800 and $950 pre-split was the biggest mistake of his career. The Broadcom buy looks like a deliberate attempt not to repeat it.

Photo by SOPA Images on Getty Images

Why Broadcom is the AI chip stock smart money keeps gravitating to

Most retail investors still think of Nvidia (NVDA) when they hear "AI chips." But Broadcom designs the custom AI accelerators (called XPUs or ASICs) that the world's biggest tech companies use when they want to stop paying Nvidia's premium.

Application-specific integrated circuits, or ASICs, are chips built for one workload only. They are cheaper and more power-efficient than general-purpose GPUs for the specific job they are designed to do.

Broadcom's customer list now includes Google, Meta, ByteDance, Anthropic, Fujitsu, and OpenAI, per Investing.com's research note. Two more hyperscalers remain unnamed.

The numbers behind the AI revenue surge:

• $73 billion AI backlog, with CEO Hock Tan citing "line of sight" to over $100 billion in annual AI chip revenue by 2027
• Q1 FY2026 revenue of $19.31 billion, up 29% year over year, per Broadcom's earnings release
• AI semiconductor revenue of $8.4 billion in Q1, up 106% year over year
• Q2 guidance of $22 billion total revenue with $10.7 billion in AI sales, up 140% year over year

For Anthropic alone, Broadcom is delivering 1 gigawatt of TPU compute capacity in 2026, scaling to more than 3 gigawatts in 2027.

How Broadcom stock stacks up against the market

Broadcom closed at $425.19 on May 15, the same day Druckenmiller's 13F dropped. The stock now sits within striking distance of its 52-week high of $442.36, according to WallStreetZen.

Here is how AVGO has performed against the broader market and its closest AI rival:

• 1 month: AVGO +7.2% vs. S&P 500 roughly +5%
• 3 months: AVGO +27.9% vs. S&P 500 roughly +10%
• 1 year: AVGO +83% vs. S&P 500 roughly +15%

Wall Street remains overwhelmingly bullish. The consensus 12-month price target sits at $477, with TD Cowen recently lifting its target to $500 and Wells Fargo pushing to $545, citing underestimated AI infrastructure demand.

What Druckenmiller's other Q1 buys say about where smart money is rotating

The Broadcom buy is only part of the story. Druckenmiller also opened a 1.89-million-share position in Caris Life Sciences, a precision oncology company using AI for cancer diagnostics, and added Revolution Medicines, a clinical-stage cancer drug developer.

That fits a public thesis he laid out in a February Morgan Stanley interview, where he called biotech "the best application of AI," specifically pointing to drug discovery, diagnostics, and patient monitoring.

The Alphabet and Amazon exits do not look like an "AI is over" call. They read more like a rotation from crowded mega-cap AI trades into picks-and-shovels infrastructure plays like Broadcom and underowned AI-adjacent healthcare names.

What this means for ordinary investors watching Broadcom

There's a six-week gap built into every 13F. Druckenmiller's positions reflect where Duquesne stood on March 31, 2026, but the filing only became public on May 15. Much of the rotation may already be baked into Broadcom's price.

A few practical considerations before chasing the trade:

• Broadcom is not cheap. The stock trades at roughly 80 times trailing earnings and 31 times forward, per CNBC data. It is pricing in continued AI dominance through 2027.
• The June 3 earnings report is the next major catalyst. Watch the $10.7 billion Q2 AI revenue guide. Miss it and the multiple compresses fast.
• Customer concentration is real. Anthropic alone could account for roughly $21 billion in 2026 AVGO revenue, per analyst estimates. Any slowdown in Anthropic's compute spend matters.
• Druckenmiller flips fast. He built and exited his Alphabet stake within two quarters. His Broadcom thesis could change just as quickly.

The bigger signal across this 13F cycle

Druckenmiller is the third major fund manager in this 13F cycle to make a sharp pivot into AI infrastructure. Bill Ackman poured roughly $2 billion into Microsoft, and Berkshire Hathaway, under Greg Abel, bought Alphabet while exiting Amazon, Visa, and Mastercard.

Three legendary investors. Three different mega-cap exits. One common destination: AI infrastructure stocks with locked-in multi-year customer contracts.

For ordinary investors, the takeaway is not to mirror the trade. It is to ask whether your AI exposure is concentrated in one or two crowded mega-cap names, or spread across the picks-and-shovels companies smart money is rotating into.

Druckenmiller can be wrong, and he admits as much. But when he moves this decisively into a single AI infrastructure name after publicly regretting his Nvidia exit, it is worth understanding why.

Related: Stan Druckenmiller reveals the one stock he regrets selling

The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

This story was originally published May 17, 2026 at 4:03 PM.